Increased risk of myocardial infarction with dabigatran: Fact or fiction?

Ada F. Giglio, Eloisa Basile, Pasquale Santangeli, Luigi Di Biase, Francesco Trotta, Andrea Natale

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarction, especially in high-risk patients. However, as shown in our article, current evidence is inconclusive on this topic; more data are needed to detail this hypothetical association, and other considerations, such as the well-known protective effect of warfarin against ACS, should be taken into account as a possible explanation.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalJournal of Cardiovascular Medicine
Volume15
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Myocardial Infarction
Venous Thromboembolism
Acute Coronary Syndrome
Antithrombins
Warfarin
Secondary Prevention
Embolism
Atrial Fibrillation
Orthopedics
Stroke
Clinical Trials
Safety
Dabigatran

Keywords

  • atrial fibrillation
  • dabigatran
  • myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Increased risk of myocardial infarction with dabigatran : Fact or fiction? / Giglio, Ada F.; Basile, Eloisa; Santangeli, Pasquale; Di Biase, Luigi; Trotta, Francesco; Natale, Andrea.

In: Journal of Cardiovascular Medicine, Vol. 15, No. 1, 2014, p. 19-26.

Research output: Contribution to journalArticle

Giglio, Ada F. ; Basile, Eloisa ; Santangeli, Pasquale ; Di Biase, Luigi ; Trotta, Francesco ; Natale, Andrea. / Increased risk of myocardial infarction with dabigatran : Fact or fiction?. In: Journal of Cardiovascular Medicine. 2014 ; Vol. 15, No. 1. pp. 19-26.
@article{8b8a365779f141f7ba5741ff516c5564,
title = "Increased risk of myocardial infarction with dabigatran: Fact or fiction?",
abstract = "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarction, especially in high-risk patients. However, as shown in our article, current evidence is inconclusive on this topic; more data are needed to detail this hypothetical association, and other considerations, such as the well-known protective effect of warfarin against ACS, should be taken into account as a possible explanation.",
keywords = "atrial fibrillation, dabigatran, myocardial infarction",
author = "Giglio, {Ada F.} and Eloisa Basile and Pasquale Santangeli and {Di Biase}, Luigi and Francesco Trotta and Andrea Natale",
year = "2014",
doi = "10.2459/JCM.0b013e328364beb8",
language = "English (US)",
volume = "15",
pages = "19--26",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Increased risk of myocardial infarction with dabigatran

T2 - Fact or fiction?

AU - Giglio, Ada F.

AU - Basile, Eloisa

AU - Santangeli, Pasquale

AU - Di Biase, Luigi

AU - Trotta, Francesco

AU - Natale, Andrea

PY - 2014

Y1 - 2014

N2 - Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarction, especially in high-risk patients. However, as shown in our article, current evidence is inconclusive on this topic; more data are needed to detail this hypothetical association, and other considerations, such as the well-known protective effect of warfarin against ACS, should be taken into account as a possible explanation.

AB - Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarction, especially in high-risk patients. However, as shown in our article, current evidence is inconclusive on this topic; more data are needed to detail this hypothetical association, and other considerations, such as the well-known protective effect of warfarin against ACS, should be taken into account as a possible explanation.

KW - atrial fibrillation

KW - dabigatran

KW - myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84894091265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894091265&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e328364beb8

DO - 10.2459/JCM.0b013e328364beb8

M3 - Article

C2 - 24492353

AN - SCOPUS:84894091265

VL - 15

SP - 19

EP - 26

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 1

ER -